2017
DOI: 10.1111/dmcn.13532
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review

Abstract: Evidence to prove (or disprove) the efficacy of oral drugs in dyskinetic cerebral palsy is low. The most investigated drugs, trihexyphenidyl and levodopa, show contradictory results. Tetrabenazine, levetiracetam, and gabapentin efficacy should be studied in more detail. Lack of evidence is partially due to the inconsistency of classifications and outcome measures used. Outcome measures should be selected within the framework of the International Classification of Functioning, Disability and Health in next clin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

4
32
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 30 publications
(37 citation statements)
references
References 56 publications
(148 reference statements)
4
32
0
1
Order By: Relevance
“…Complete dopa responsiveness is suggestive of a primary neurotransmitter condition and sometimes other monogenic disorders such as PARKIN deletions; however, varying dopamine responsiveness can be observed in some other genetic nonprogressive disorders (DNAJC12, DYT11, paroxyxmal kinesigenic and nonkinesigenic dyskinesia, and pyruvate dehydrogenase complex deficiency), genetic‐progressive disorders (ataxia telangiectasia, chorea acanthocytosis, DJ‐1, FBX07, Kufor‐Rakeb disease, nuclear inclusion body disease, PINK1, pantothenate kinase associated neurodegeneration, PLA2G6 associated neurodegeneration, pontocerebellar hypoplasia type 2, SCA2, SCA3, SOX6, SPG11, and xeroderma pigmentosum), and, to a lesser extent, in acquired disorders such as movement disorders with lupus, organophosphate poisoning, subacute sclerosing panencephalitis, postencephalitic dystonia, or extrapontine myelinolysis. The role of l ‐dopa in management of dystonic cerebral palsy (CP) is questionable and results from previous studies are contradictory …”
Section: Symptomatic Therapiesmentioning
confidence: 99%
See 3 more Smart Citations
“…Complete dopa responsiveness is suggestive of a primary neurotransmitter condition and sometimes other monogenic disorders such as PARKIN deletions; however, varying dopamine responsiveness can be observed in some other genetic nonprogressive disorders (DNAJC12, DYT11, paroxyxmal kinesigenic and nonkinesigenic dyskinesia, and pyruvate dehydrogenase complex deficiency), genetic‐progressive disorders (ataxia telangiectasia, chorea acanthocytosis, DJ‐1, FBX07, Kufor‐Rakeb disease, nuclear inclusion body disease, PINK1, pantothenate kinase associated neurodegeneration, PLA2G6 associated neurodegeneration, pontocerebellar hypoplasia type 2, SCA2, SCA3, SOX6, SPG11, and xeroderma pigmentosum), and, to a lesser extent, in acquired disorders such as movement disorders with lupus, organophosphate poisoning, subacute sclerosing panencephalitis, postencephalitic dystonia, or extrapontine myelinolysis. The role of l ‐dopa in management of dystonic cerebral palsy (CP) is questionable and results from previous studies are contradictory …”
Section: Symptomatic Therapiesmentioning
confidence: 99%
“…In some genetic dystonias, such as DYT1 (and personal experience) or DYT11, trihexiphenidyl can be highly effective. Adverse events are common and include anticholinergic side effects such as constipation, ileus, dry mouth, blurred vision, urinary retention, and cardiovascular alterations . In addition, anticholinergics can cause confusion, depression, personality change, and cognitive issues …”
Section: Symptomatic Therapiesmentioning
confidence: 99%
See 2 more Smart Citations
“…The systematic review by Masson et al demonstrates that the current evidence does not strongly suggest efficacy of any oral medications in dyskinetic CP . It is important not to misinterpret this result as a lack of efficacy.…”
mentioning
confidence: 99%